Alosetron: A case study in regulatory capture, or a victory for patients' rights?

Ray Moynihan

doi:10.1136/bmj.325.7364.592

Alosetron: A case study in regulatory capture, or a victory for patients' rights?

Ray Moynihan^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate/opinion › Professional

48 Citations (Scopus)

Abstract

Senior members of the FDA's advisory committee warn of more deaths if alosetron (Lotronex) is relaunched, as a former insider speaks out about the US regulator's close relationship with Big Pharma

Original language	English
Pages (from-to)	592-595
Number of pages	4
Journal	British Medical Journal
Volume	325
Issue number	7364
DOIs	https://doi.org/10.1136/bmj.325.7364.592
Publication status	Published - 14 Sept 2002
Externally published	Yes

Access to Document

10.1136/bmj.325.7364.592

Cite this

@article{9ebf8f19fabf40b1b5d61eae41fc6822,

title = "Alosetron: A case study in regulatory capture, or a victory for patients' rights?",

abstract = "Senior members of the FDA's advisory committee warn of more deaths if alosetron (Lotronex) is relaunched, as a former insider speaks out about the US regulator's close relationship with Big Pharma",

author = "Ray Moynihan",

year = "2002",

month = sep,

day = "14",

doi = "10.1136/bmj.325.7364.592",

language = "English",

volume = "325",

pages = "592--595",

journal = "British Medical Journal",

issn = "0959-8146",